Physician profile
Saritha Uppala
NPI 1588829865
$2,841.41
in general payments reported to CMS, 2019-2025
26 companies · $61.93 in 2025
The $61.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $865 · 2021: $225 · 2022: $392 · 2023: $643 · 2024: $243 · 2025: $61.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $925.14 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $374.86 | 2019-2025 | Farxiga, Breztri |
| Kowa Pharmaceuticals America, INC. | $239.00 | 2019-2021 | |
| Lilly USA, LLC | $186.61 | 2020-2024 | Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $135.79 | 2019-2020 | |
| Amgen INC. | $118.26 | 2019-2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $107.99 | 2020-2021 | |
| Glaxosmithkline, LLC. | $89.91 | 2023-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $85.84 | 2019-2020 | |
| Dexcom, INC. | $82.81 | 2021-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $70.84 | 2020-2023 | Tirosint, Licart |
| Allergan, INC. | $61.79 | 2019-2020 | |
| Vivus LLC | $61.38 | 2022 | |
| Shield Therapeutics INC | $57.17 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $47.71 | 2023-2024 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34.67 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.44 | 2022 | |
| Abbott Laboratories | $21.44 | 2023 | Freestyle Libre 2 |
| Paratek Pharmaceuticals, INC. | $18.88 | 2025 | Nuzyra |
| Daiichi Sankyo INC. | $17.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.48 | 2022 | |
| Esperion Therapeutics, INC. | $13.99 | 2024 | Nexletol |
| Rhythm Pharmaceuticals, INC. | $13.08 | 2022 | |
| Genentech USA, INC. | $11.74 | 2019 | |
| Astellas Pharma US INC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saritha Uppala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.